Mallinckrodt acquires Therakos Inc. for $1.325 billion and with it Therakos Photopheresis

Mallinckrodt plc and The Gores Group, a global investment firm, announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc., a leading immunotherapy company in a transaction valued at approximately $1.325 billion. Therakos is the global leader in autologous immune cell therapy delivered through extracorporeal photopheresis (ECP), and is focused on providing innovative treatment platforms that harness the power of patients' immune systems to fight disease. Therakos® Photopheresis is approved by the FDA for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) in persons who have not been responsive to other forms of treatment. Outside the U.S., Therakos Photopheresis is also broadly approved for ECP, and used in immune-modulating applications in a variety of conditions including CTCL, graft-versus-host disease, Crohn's disease, solid organ transplants and other diseases.